🚀 VC round data is live in beta, check it out!
Jade Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jade Biosciences and similar public comparables like Tempo Scan Pacific, Abclon, Prime Medicine, Zentiva and more.
Jade Biosciences Overview
About Jade Biosciences
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Founded
2024
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$535M
Jade Biosciences Financials
Jade Biosciences reported last 12-month revenue of —.
In the same LTM period, Jade Biosciences generated — in gross profit and had net loss of ($127M).
Revenue (LTM)
Jade Biosciences P&L
In the most recent fiscal year, Jade Biosciences reported revenue of — and net income of —.
Jade Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Net Profit | ($127M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jade Biosciences Stock Performance
Jade Biosciences has current market cap of $733M, and enterprise value of $535M.
Market Cap Evolution
Jade Biosciences' stock price is $14.86.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $535M | $733M | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJade Biosciences Valuation Multiples
Jade Biosciences Financial Valuation Multiples
As of March 7, 2026, Jade Biosciences has market cap of $733M and EV of $535M.
Equity research analysts estimate Jade Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jade Biosciences has a P/E ratio of (5.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $733M | XXX | $733M | XXX | XXX | XXX |
| EV (current) | $535M | XXX | $535M | XXX | XXX | XXX |
| EV/EBIT | (4.4x) | XXX | — | XXX | XXX | XXX |
| P/E | (5.7x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jade Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jade Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| Abclon | XXX | XXX | XXX | XXX | XXX | XXX |
| Prime Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmicell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jade Biosciences M&A Activity
Jade Biosciences acquired XXX companies to date.
Last acquisition by Jade Biosciences was on XXXXXXXX, XXXXX. Jade Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jade Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJade Biosciences Investment Activity
Jade Biosciences invested in XXX companies to date.
Jade Biosciences made its latest investment on XXXXXXXX, XXXXX. Jade Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jade Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jade Biosciences
| When was Jade Biosciences founded? | Jade Biosciences was founded in 2024. |
| Where is Jade Biosciences headquartered? | Jade Biosciences is headquartered in United States. |
| Who is the CEO of Jade Biosciences? | Jade Biosciences' CEO is Tom Frohlich. |
| Is Jade Biosciences publicly listed? | Yes, Jade Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Jade Biosciences? | Jade Biosciences trades under JBIO ticker. |
| When did Jade Biosciences go public? | Jade Biosciences went public in 2025. |
| Who are competitors of Jade Biosciences? | Jade Biosciences main competitors are Tempo Scan Pacific, Abclon, Prime Medicine, Zentiva. |
| What is the current market cap of Jade Biosciences? | Jade Biosciences' current market cap is $733M. |
| Is Jade Biosciences profitable? | No, Jade Biosciences is not profitable. |
| What is the current net income of Jade Biosciences? | Jade Biosciences' last 12 months net income is ($127M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.